ebook_ADHD2019_engl.

The World Federation of ADHD Guide 35 of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties. Other authors report no conflict of interest. REFERENCES 1. Scassellati C, Bonvicini C, Faraone SV, Gennarelli M. Biomarkers and attention-deficit/hyperactivity di- sorder: a systematic review and meta-analyses. J Am Acad Child Adolesc Psychiatry. 2012;51(10):1003-1019. e20. 2. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol. 2002;67(1):53-83. 3. Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. 2009;302(10):1084-91. 4. Nieoullon A, Coquerel A. Dopamine: a key regulator to adapt action, emotion, motivation and cognition. Curr Opin Neurol. 2003;16 Suppl 2:S3-9. 5. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The roles of dopamine and noradrenali- ne in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2011;69(12):e145-57. 6. Ziegler S, Pedersen ML, Mowinckel AM, Biele G. Modelling ADHD: A review of ADHD theories throu- gh their predictions for computational models of decision-making and reinforcement learning. Neurosci Biobehav Rev. 2016;71:633-656. 7. Kuczenski R, Segal DS. Stimulant actions in rodents: implications for attention-deficit/hyperactivity disor- der treatment and potential substance abuse. Biol Psychiatry. 2005;57(11):1391-6. 8. Kuczenski R, Segal DS. Differential effects of D- and L-amphetamine and methylphenidate on rat striatal dopamine biosynthesis. Eur J Pharmacol. 1975;30(2):244-51. 9. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 1996;379(6566):606-12. 10. van der Voet M, Harich B, Franke B, Schenck A. ADHD-associated dopamine transporter, latrophi- lin and neurofibromin share a dopamine-related locomotor signature in Drosophila. Mol Psychiatry. 2016;21(4):565-73. 11. van der Kooij MA, Glennon JC.Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder. Neurosci Biobehav Rev. 2007;31(4):597-618. 12. Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiatry. 2012;169(3):264-72. 13. Bralten J, Franke B, Waldman I, Rommelse N, Hartman C, Asherson P, et al. Candidate genetic pathways for attention-deficit/hyperactivity disorder (ADHD) show association to hyperactive/impulsive symptoms in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2013;52(11):1204-1212.e1. 14. Arnsten AF, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav. 2011;99(2):211- 6. 15. de la Peña JB, Dela Peña IJ, Custodio RJ, Botanas CJ, Kim HJ, Cheong JH. Exploring the validity of proposed transgenic animal models of attention-deficit hyperactivity disorder (ADHD). Mol Neurobiol. 2018;55(5):3739-3754.